Buy Cipla Ltd For Target Rs. 1695 By Geojit Financial Services Ltd
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Goa Clearance paves the way for Abraxane
Cipla Ltd is a holding company that operates as a pharmaceutical company. Its strategic business units comprise Active Pharmaceutical Ingredients (APIs), Respiratory, and Cipla Global Access. Geographically, the company operates in India, the US, South Africa and the Rest of the World.
* In Q2FY25, Cipla's consolidated revenue grew 5.6% YoY to Rs. 7,051cr, driven by a 28.9% YoY growth in South Africa to Rs. 799cr and a 19.1% YoY growth in emerging markets and Europe to Rs. 806cr.
* Revenue from Indian operations grew a marginal 4.7% YoY to Rs. 2,948cr, driven by strong chronic therapy sales and 21% YoY growth in consumer health franchise. However, seasonality impacted the Acute category growth, but the business is expected to recover in the coming quarters.
* Cipla's North America business rose 5.2% YoY to Rs. 1,986cr, driven by its differentiated portfolio, but was impacted by lower sales of Lanreotide due to a partner's manufacturing plant expansion, with sales expected to rebound in Q4FY25. • EBITDA increased 8.8% YoY to Rs. 1,886cr and EBITDA margin expanded 70 bps to 26.7%, primarily driven by a favourable product mix.
Outlook & Valuation
Cipla delivered a robust financial performance in Q2FY25, driven by its diversified business segments, strong growth momentum and improving profitability. The company's focus on resolving regulatory issues, expanding production capacity and pursuing approval in the Chinese market provide a potential upside, while the seasonal demand for respiratory products and a strong chronic therapy sales pipeline offer a stable revenue stream. The recent clearance of the Goa facility paves the way for Abraxane’s launch. However, concerns persist about the delayed launch of gAdvair due to the pending US FDA compliance of its Indore plant. Despite these concerns, we remain positive, and reiterate our BUY rating on the stock with a revised target price of Rs. 1,695, based on 26x FY26E adjusted EPS.
For More Geojit Financial Services Ltd Disclaimer https://www.geojit.com/disclaimer
SEBI Registration Number: INH20000034
